Loading stock data…
Takeda Pharmaceutical Company L (TAK)
$18.32-0.13 (-0.70%)
Market ClosedLast close Sep 8
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $18.32 with a market capitalization of $58.9B. Wall Street consensus targets $22.80 (3 analysts), implying a +24.5% move over the next 12 months. The stock is currently near its 52-week high of $18.90, remaining 9.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.22T↑ | $1.09T↓ | $1.19T↑ | $1.11T↑ | $1.11T |
| Gross Profit | $813.22B↑ | $688.84B↓ | $790.55B↑ | $732.74B↑ | $722.01B |
| Operating Income | $201.42B↑ | $42.07B↓ | $168.82B↑ | $69.00B↓ | $184.56B |
| Net Income | $113.20B↑ | -$368.47B↓ | $103.64B↑ | -$11.80B↓ | $124.24B |
Peer Comparison
JNJUNHPFE
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therap...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.86B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.16%
Volume
Today's trading volume
3.14M
Recent News
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Takeda and Weave Bio collaborate on AI-driven automation in drug development
The joint effort began with AI-assisted IND submission preparation and has since expanded to HAQ and RTQ processes.
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
Protagonist Therapeutics recently reported that the U.S. FDA approved MIMRYLO (rusfertide), the first hepcidin mimetic peptide therapy for adults with polycythemia vera, a rare blood cancer. This regulatory milestone also activates milestone payments from partner Takeda, underlining how MIMRYLO’s unique mechanism could reshape treatment options in this indication. We’ll now examine how FDA approval of MIMRYLO and the associated Takeda milestone payments influence Protagonist Therapeutics’...